This invention provides novel 2-substituted-3-quinuclidinyl arylcarboxamides and arylthiocarboxamides and corresponding arylcarboxylates which have utility as therapeutic agents which exhibit gastric prokinetic, antiemetic, anxiolytic and 5-HT (serotonin) antagonist effects in warm blooded animals. Illustrative of an invention compound is 5-chloro-2-methoxy-4-(methylamino)-N-[2-(1-piperidinylmethyl)-1-azabicyclo [2.2.2]oct-3-yl]benzamide: ##STR1## or a pharmaceutically acceptable salt thereof.

The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which .alpha.7 is known to be involved.

This invention provides compounds of the formula I ##STR1## wherein, R.sup.1, R.sup.2, and R.sup.3 are independently [a first halogen atom,] fluorine, chlorine, bromine, iodine, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, or alkynoxy, wherein R.sup.2 and R.sup.3 can also independently be H, wherein at least one of R.sup.1, R.sup.2, and R.sup.3 is [a second halogen atom] fluorine, bromine, iodine or is substituted with [a second halogen atom,] fluorine, bromine or iodine and R.sup.4 is H or lower alkyl. The invention also provides precursors of formula I, radioactive analogs of formula I, and methods of using the compounds for the identification of 5-HT-3 receptors and the detection and treatment of abnormal conditions associated therewith.

The invention provides compounds of Formula I: ##STR00001## wherein Azabicyclo is ##STR00002## W is a six-membered heterocyclic ring system having 1 2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms within either or both rings, provided that no nitrogen is at a bridge of the bicyclic-six-six-fused-ri- ng system, and further having 1 2 substitutents independently selected from R.sub.3.These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat diseases or conditions in which .alpha.7 is known to be involved.

The invention provides compounds of Formula I: ##STR1## These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which .alpha.7 is known to be involved.